EyePoint specializes in the development of sustained-release drug delivery to treat debilitating diseases of the eye and other localized, chronic conditions.
EyePoint’s proprietary DurasertTM Technology allows for sustained-release delivery of small molecules for up to three years with a single injection. The technology has been utilized in four FDA-approved products – most recently in YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, approved by the FDA on October 12, 2018.
EyePoint’s proprietary VerisomeTM technology allows for sustained release of small molecules in a suspension that can release over 1-6 months with a single injection. The technology has been utilized in DEXYCUTM (dexamethasone intraocular suspension) 9%, approved by U.S. Food and Drug Administration (FDA) on February 9, 2018.
EyePoint’s proven DurasertTM Technology is a miniaturized, injectable, sustained-release drug delivery system for small molecules that can last for up to three years. The implant can be administered in an office setting through a needle as small as 25-gauge. To date, four products utilizing the technology have been approved by the FDA. These products include YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, commercialized in the U.S. by EyePoint, ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, licensed to Alimera Sciences, and RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg and VITRASERT® (ganciclovir) 4.5 mg, licensed to Bausch & Lomb.
Durasert Technology for the delivery of small molecules provides the following:
- Bioerodible or non-erodible devices
- Linear sustained-release kinetics
- Customizable duration of release (from months up to three years)
- Highly efficient drug loading (up to 80%)
- Administration in an office setting
- Injectable via needles as small as 27-gauge
The Verisome drug delivery technology is the most advanced, yet simplest, system for controlling the release of therapeutic agents in the eye for extended periods of time. The Verisome® technology’s versatility can support a wide range of products individually formulated to meet the requirements of a given active agent and the demands of a specific clinical situation.
Customizable duration from one week to several months
Injectible via needle
Could be formulated with small and large molecule compounds
EyePoint has successfully created partnerships with some of the world’s leading pharmaceutical companies. EyePoint seeks additional strategic partners to collaborate on the development of new sustained release drug suspensions and devices; to access complementary research, technology and development capabilities; and to expand our product portfolio.
EyePoint technologies have broad applicability across therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. EyePoint’s intellectual property portfolio consists of our proven DurasertTM and VerisomeTM Technology platforms for the delivery of small molecules.
For more information about possible collaborations, please contact us: